- Previous Close
6.520 - Open
6.200 - Bid 5.880 x --
- Ask 5.940 x --
- Day's Range
5.730 - 6.180 - 52 Week Range
5.180 - 9.100 - Volume
369,200 - Avg. Volume
243,867 - Market Cap (intraday)
642.581M - Beta (5Y Monthly) --
- PE Ratio (TTM)
8.07 - EPS (TTM)
0.730 - Earnings Date --
- Forward Dividend & Yield 0.06 (0.92%)
- Ex-Dividend Date Jun 13, 2025
- 1y Target Est
--
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. engages in the research, development, production and sales of biopharmaceutical products and medical devices. It offers Guyoudao, a recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair product; Jilifen, a Human granulocyte colony stimulating factor injection for neutropenia; and Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia. The company also provides Jitansu, a fosaprepitant dimeglumine injection for chemotherapy-induced nausea and vomiting; Jifuwei, a fulvestrant injection for advanced breast cancer; Yirojia, an enoxaparin sodium injection for Venous thromboembolic diseases; Jipalin, a low molecular weight heparin sodium injection for Venous thromboembolic diseases; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by radiation therapy, chemotherapy or postoperatively. It offers its products in the areas of orthopedics, metabolic diseases, oncology, and hematology. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Gene Engineering Co., Ltd. in April 2025. The company was incorporated in 1993 and is based in Hangzhou, China.
www.china-gene.comRecent News: 2566.HK
View MorePerformance Overview: 2566.HK
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2566.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2566.HK
View MoreValuation Measures
Market Cap
1.60B
Enterprise Value
1.07B
Trailing P/E
8.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.91
Price/Book (mrq)
0.98
Enterprise Value/Revenue
0.73
Enterprise Value/EBITDA
5.66
Financial Highlights
Profitability and Income Statement
Profit Margin
10.12%
Return on Assets (ttm)
6.08%
Return on Equity (ttm)
11.47%
Revenue (ttm)
1.37B
Net Income Avi to Common (ttm)
138.6M
Diluted EPS (ttm)
0.730
Balance Sheet and Cash Flow
Total Cash (mrq)
611.38M
Total Debt/Equity (mrq)
7.95%
Levered Free Cash Flow (ttm)
--